DK2224950T3 - Medikament til behandling af kræft i bugspytkirtlen - Google Patents
Medikament til behandling af kræft i bugspytkirtlen Download PDFInfo
- Publication number
- DK2224950T3 DK2224950T3 DK08864169T DK08864169T DK2224950T3 DK 2224950 T3 DK2224950 T3 DK 2224950T3 DK 08864169 T DK08864169 T DK 08864169T DK 08864169 T DK08864169 T DK 08864169T DK 2224950 T3 DK2224950 T3 DK 2224950T3
- Authority
- DK
- Denmark
- Prior art keywords
- asparaginase
- suspension
- treatment
- use according
- medicament
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01001—Asparaginase (3.5.1.1)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (16)
1. Suspension af røde blodlegemer, der indkapsler asparaginase, som et medikament til anvendelse i behandlingen af kræft i bugspytkirtlen.
2. Terapeutisk sammensætning eller medikament omfattende en suspension af røde blodlegemer, der indkapsler asparaginase, til anvendelse i behandlingen af kræft i bugspytkirtlen.
3. Suspension, sammensætning eller medikament til anvendelse ifølge krav 1 eller 2 til forhøjelse af patientoverlevelse.
4. Suspension, sammensætning eller medikament til anvendelse ifølge et hvilket som helst af de foregående krav, der foreligger i en brugsfærdig form eller til fortynding før brug.
5. Suspension, sammensætning eller medikament til anvendelse ifølge krav 4, hvor, for en form beregnet til fortynding før brug, hæmatokritten før fortynding ligger mellem 60 og 90 %.
6. Suspension, sammensætning eller medikament til anvendelse ifølge et hvilket som helst af krav 1 til 5, hvor den brugsfærdige suspensions hæmatokrit ligger mellem ca. 40 og ca. 70 %, fortrinsvis mellem ca. 45 og ca. 55 % og bedre ca. 50 %.
7. Suspension, sammensætning eller medikament til anvendelse ifølge et hvilket som helst af de foregående krav, indeholdende mellem 30 og 300 IU asparaginase pr. ml, fortrinsvis mellem 70 og 150 IU pr. ml.
8. Suspension, sammensætning eller medikament til anvendelse ifølge et hvilket som helst af de foregående krav, yderligere indeholdende et kemoterapeutisk middel.
9. Suspension, sammensætning eller medikament til anvendelse ifølge krav 8, indeholdende gemcitabin, cisplatin, oxaliplatin eller 5-fluoruracil i kombination med et platinderivat, for eksempel cisplatin eller oxaliplatin, som det kemoterapeutiske middel.
10. Anvendelse af røde blodlegemer, der indkapsler asparaginase, til fremstilling af et medikament beregnet til behandling af kræft i bugspytkirtlen.
11. Anvendelse ifølge krav 10 til forhøjelse af patientoverlevelse.
12. Anvendelse ifølge krav 10 eller 11 til fremstilling af et medikament indeholdende mellem 30 og 300 IU asparaginase pr. ml, fortrinsvis mellem 70 og 150 IU pr. ml.
13. Anvendelse ifølge et hvilket som helst af krav 10 til 12 til fremstilling af et medikament i form af en suspension på 10 til 250 ml.
14. Anvendelse ifølge et hvilket som helst af krav 10 til 13 til fremstilling af et medikament beregnet til frigivelse af 20 til 500 IU, fortrinsvis fra 50 til 500 IU, asparaginase pr. kg kropsvægt og pr. dosis.
15. Anvendelse ifølge et hvilket som helst af krav 10 til 14, hvor en suspension af røde blodlegemer, der indkapsler asparaginase, og et kemoterapeutisk middel anvendes til fremstilling af medikamentet til behandling af kræft i bugspytkirtlen.
16. Anvendelse ifølge et hvilket som helst af krav 10 til 14, hvor medikamentet er beregnet til indgivelse til en patient, der også indgives et kemoterapeutisk middel.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0760345A FR2925339B1 (fr) | 2007-12-24 | 2007-12-24 | Medicament pour le traitement du cancer du pancreas |
| PCT/EP2008/068289 WO2009080837A1 (en) | 2007-12-24 | 2008-12-24 | Medicament for the treatment of cancer of the pancreas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2224950T3 true DK2224950T3 (da) | 2015-03-23 |
Family
ID=39322665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08864169T DK2224950T3 (da) | 2007-12-24 | 2008-12-24 | Medikament til behandling af kræft i bugspytkirtlen |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8974802B2 (da) |
| EP (1) | EP2224950B1 (da) |
| JP (2) | JP5932218B2 (da) |
| KR (1) | KR101605838B1 (da) |
| CN (2) | CN101932335A (da) |
| AU (1) | AU2008339918B2 (da) |
| CA (1) | CA2710646C (da) |
| DK (1) | DK2224950T3 (da) |
| ES (1) | ES2537315T3 (da) |
| FR (1) | FR2925339B1 (da) |
| HK (1) | HK1224200A1 (da) |
| HR (1) | HRP20150498T1 (da) |
| IL (1) | IL206563A (da) |
| PL (1) | PL2224950T3 (da) |
| PT (1) | PT2224950E (da) |
| SI (1) | SI2224950T1 (da) |
| WO (1) | WO2009080837A1 (da) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2938332B1 (fr) * | 2008-11-07 | 2011-11-25 | Erytech Pharma | Test predictif de la neutralisation de l'activite asparaginase |
| US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| US9518087B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| RU2667639C2 (ru) * | 2012-03-21 | 2018-09-21 | Эритек Фарма | Лекарственное средство для лечения острого миелоидного лейкоза (омл) |
| AU2014348683B2 (en) | 2013-11-18 | 2020-11-05 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
| FR3017299B1 (fr) | 2014-02-12 | 2018-05-18 | Erytech Pharma | Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur |
| US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| EP3909603A1 (en) | 2014-02-21 | 2021-11-17 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Glycotargeting therapeutics |
| US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
| WO2015153102A1 (en) | 2014-04-01 | 2015-10-08 | Rubius Therapeutics, Inc. | Methods and compositions for immunomodulation |
| CA2998059A1 (en) * | 2015-09-25 | 2017-03-30 | Dsm Ip Assets B.V. | Asparaginase |
| WO2017050651A1 (en) * | 2015-09-25 | 2017-03-30 | Dsm Ip Assets B.V. | Asparaginase |
| CA2998263A1 (en) * | 2015-09-25 | 2017-03-30 | Dsm Ip Assets B.V. | Asparaginase |
| DK3402491T3 (da) | 2016-01-11 | 2022-02-14 | Rubius Therapeutics Inc | Sammensætninger og fremgangsmåder angående flermodale terapeutiske cellesystemer for kræftindikationer |
| BR112019011138A2 (pt) * | 2016-12-02 | 2019-10-01 | Rubius Therapeutics Inc | composições e métodos relacionados com sistemas celulares para penetração em tumores sólidos |
| EP3638296A1 (en) | 2017-06-16 | 2020-04-22 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
| US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
| WO2020043321A1 (en) | 2018-08-31 | 2020-03-05 | Stichting Katholieke Universiteit | Synergistic combinations of amino acid depletion agent sensitizers (aadas) and amino acid depletion agents (aada), and therapeutic methods of use thereof |
| CA3178252A1 (en) | 2020-05-11 | 2021-11-18 | Erytech Pharma | Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof |
| WO2023067200A1 (en) * | 2021-10-24 | 2023-04-27 | Erytech Pharma | Asparaginase encapsulated in red blood cells for the treatment of pancreatic cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2873925B1 (fr) * | 2004-08-05 | 2006-10-13 | Erytech Pharma Soc Par Actions | Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes |
| US7985548B2 (en) | 2006-03-03 | 2011-07-26 | The United States Of America As Represented By The Department Of Health And Human Services | Materials and methods directed to asparagine synthetase and asparaginase therapies |
-
2007
- 2007-12-24 FR FR0760345A patent/FR2925339B1/fr active Active
-
2008
- 2008-12-24 WO PCT/EP2008/068289 patent/WO2009080837A1/en active Application Filing
- 2008-12-24 AU AU2008339918A patent/AU2008339918B2/en active Active
- 2008-12-24 ES ES08864169.1T patent/ES2537315T3/es active Active
- 2008-12-24 JP JP2010540140A patent/JP5932218B2/ja active Active
- 2008-12-24 PL PL08864169T patent/PL2224950T3/pl unknown
- 2008-12-24 US US12/810,164 patent/US8974802B2/en active Active
- 2008-12-24 CA CA2710646A patent/CA2710646C/en active Active
- 2008-12-24 KR KR1020107016332A patent/KR101605838B1/ko active IP Right Grant
- 2008-12-24 CN CN2008801260460A patent/CN101932335A/zh active Pending
- 2008-12-24 EP EP08864169.1A patent/EP2224950B1/en active Active
- 2008-12-24 DK DK08864169T patent/DK2224950T3/da active
- 2008-12-24 PT PT88641691T patent/PT2224950E/pt unknown
- 2008-12-24 SI SI200831419T patent/SI2224950T1/sl unknown
- 2008-12-24 CN CN201610012474.7A patent/CN105617366A/zh active Pending
-
2010
- 2010-06-23 IL IL206563A patent/IL206563A/en active IP Right Grant
-
2015
- 2015-01-09 JP JP2015003254A patent/JP2015091859A/ja active Pending
- 2015-05-11 HR HRP20150498TT patent/HRP20150498T1/hr unknown
-
2016
- 2016-11-01 HK HK16112530.4A patent/HK1224200A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2224950T3 (pl) | 2015-08-31 |
| CN101932335A (zh) | 2010-12-29 |
| IL206563A0 (en) | 2010-12-30 |
| AU2008339918B2 (en) | 2012-09-20 |
| HRP20150498T1 (hr) | 2015-06-19 |
| HK1224200A1 (zh) | 2017-08-18 |
| FR2925339B1 (fr) | 2010-03-05 |
| PT2224950E (pt) | 2015-05-18 |
| CA2710646A1 (en) | 2009-07-02 |
| KR20100102676A (ko) | 2010-09-24 |
| WO2009080837A1 (en) | 2009-07-02 |
| CN105617366A (zh) | 2016-06-01 |
| ES2537315T3 (es) | 2015-06-05 |
| SI2224950T1 (sl) | 2015-08-31 |
| IL206563A (en) | 2013-09-30 |
| EP2224950A1 (en) | 2010-09-08 |
| JP2011507935A (ja) | 2011-03-10 |
| JP2015091859A (ja) | 2015-05-14 |
| KR101605838B1 (ko) | 2016-03-24 |
| US20100310612A1 (en) | 2010-12-09 |
| AU2008339918A1 (en) | 2009-07-02 |
| EP2224950B1 (en) | 2015-02-25 |
| CA2710646C (en) | 2017-08-22 |
| JP5932218B2 (ja) | 2016-06-08 |
| US8974802B2 (en) | 2015-03-10 |
| FR2925339A1 (fr) | 2009-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2224950T3 (da) | Medikament til behandling af kræft i bugspytkirtlen | |
| Rossi et al. | Erythrocyte-mediated delivery of phenylalanine ammonia lyase for the treatment of phenylketonuria in BTBR-Pahenu2 mice | |
| US20150086521A1 (en) | Medicament for the Treatment of Acute Myeloid Leukemia (AML) | |
| CA3009918C (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
| EP2249816B1 (en) | Formulation and method for the prevention and treatment of bone metastases or other bone diseases | |
| RU2744659C2 (ru) | Фармацевтическая композиция, содержащая эритроциты, в которых заключен фермент, зависимый от пиридоксальфосфата, и его кофактор | |
| ES2405258T3 (es) | Formulación y procedimiento para la prevención y el tratamiento de la manifestación esquelética de la enfermedad de Gaucher | |
| US9125876B2 (en) | Erythrocytes containing arginine deiminase | |
| RU2670070C2 (ru) | Способ получения эритроцитов, нагруженных одним или несколькими веществами, представляющими фармацевтический интерес, и полученные таким образом эритроциты | |
| US20200360495A1 (en) | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor | |
| US20160120956A1 (en) | Composition of erythrocytes encapsulating phenylalanine hydroxylase and therapeutic use thereof | |
| Kumarl et al. | Resealed erythrocytes as a carrier for drug targeting: a review | |
| Rajaram et al. | Enhancement of rifampicin bioavailability by immune enhancing nutrient (Ascorbic acid) as chitosan nanoparticles for tuberculosis therapy | |
| Kumar et al. | Resealed Erythrocytes as a Carrier for Drug Targeting: A |